- Home
- SKYE vs GP Comparison
SKYE vs GP Comparison
Compare SKYE & GP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYE | GP |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | Canada |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.2M |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SKYE | GP |
|---|---|---|
| Price | $1.69 | $0.38 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $68.00 | N/A |
| AVG Volume (30 Days) | 60.3K | ★ 214.3K |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $308.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.32 |
| 52 Week High | $2.32 | $3.38 |
Technical Indicators
Market Signals| Indicator | SKYE | GP |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 18.38 |
| Support Level | $1.56 | N/A |
| Resistance Level | $2.28 | $1.17 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 38.10 | 8.35 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About GP GreenPower Motor Company Inc.
GreenPower Motor Co Inc is a manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector. The Company operates in one reportable operating segment, being the manufacture and distribution of all electric commercial vehicles and transit, school and charter buses. Geographically the company has presence in Canada, and United States of America. The company generates majority of revenue from United States of America.